Organigram Enters Subscription Agreement with BAT for Sanity Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Source: Newsfilter
- Significant Financing: Organigram's subscription agreement with BAT will provide the company with a total of C$65 million in funding, including the purchase of 14,027,074 shares at C$3.00 each, indicating strong market support for its acquisition of Sanity Group.
- Equity Structure Adjustment: BAT will receive 2,353,379 common shares and 21,571,051 preferred shares in this transaction, with the preferred shares convertible into common shares without exceeding a 30% ownership threshold, ensuring BAT's influence within the company.
- Regulatory Approval Requirements: The acquisition and private placement investment are subject to multiple regulatory approvals, including from the Toronto Stock Exchange and Organigram's shareholders, highlighting the complexity of the transaction and its implications for corporate governance.
- Strategic Investment Intent: Through this transaction, BAT further solidifies its investment in Organigram, reflecting its long-term optimism about the cannabis market and potentially increasing its control over the company by adding board members.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTI
About BTI
British American Tobacco p.l.c. is a global multi-category consumer goods business company. The Company provides tobacco and nicotine products. Its segments include the United States, Asia Pacific Middle East and Africa, and Americas and Europe. Its product categories include Vapor, Heating Products (HPs), Modern Oral, Traditional Oral, and Combustible cigarettes. Vapor products are handheld, battery-powered devices that heat a liquid to produce an inhalable aerosol, known as vapor. HPs are devices that use heat to generate a nicotine-containing aerosol, which the user inhales. This category includes Tobacco Heated Products and Herbal Products for Heating (HPH). Modern Oral products are smoke-free oral nicotine products called nicotine pouches, designed for use in the mouth. Traditional oral products include snus and snuff. Its brands include Vuse, glo, Velo, Grizzly, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, Camel, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doseology Launches New Energy Pouches Targeting Market Opportunities
- Market Growth Potential: The global oral nicotine pouch market is projected to grow from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% CAGR, indicating strong consumer demand for smoke-free alternatives and driving investments and innovations from companies like Doseology.
- Product Innovation and Market Testing: Doseology's launch of Feed That Brain energy pouches in the U.S. marks its first direct-to-consumer initiative, aiming to provide sugar-free, smoke-free energy supplements, signifying the company's strategic positioning in the non-nicotine energy product sector, expected to attract health-conscious consumers.
- Strategic Leadership Change: The recent appointment of Larry Latowsky as Executive Chairman brings extensive industry experience from his tenure as President and CEO of Katz Group Canada, which is anticipated to drive sustainable growth in Doseology's oral stimulant platform and enhance market competitiveness.
- Equity Incentive Program: The company granted 140,000 restricted share units and 210,000 performance share units to a director, with the vesting schedule spread over 36 months, aimed at attracting and retaining executive talent to support the company's long-term strategic goals.
See More
Doseology Launches New Energy Pouches Targeting Market Opportunities
- Market Growth Potential: The global oral nicotine pouch market is projected to grow from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% CAGR, indicating strong consumer demand for smoke-free alternatives and creating market opportunities for companies like Doseology.
- Product Innovation Launch: Doseology has launched its 'Feed That Brain' energy pouches in the U.S., marking its first direct-to-consumer initiative aimed at providing sugar-free, smoke-free energy supplements that align with modern consumer preferences for health and convenience.
- Strategic Milestone: This U.S. pilot project represents a significant step for Doseology in validating oral pouch delivery as a scalable stimulant platform, with plans to evaluate consumer adoption and repeat purchase behavior, particularly targeting the demand for alternatives to traditional energy drinks.
- Leadership Change: Doseology recently appointed Larry Latowsky as Executive Chairman, whose experience from Katz Group Canada is expected to provide strategic guidance, enhance team confidence, and drive the release of long-term value.
See More
Major Retailers Continue Earnings Season This Week
- AST SpaceMobile Earnings Outlook: AST SpaceMobile, Inc. (NASDAQ:ASTS) is set to report its Q4 results after Monday's close, with Wall Street anticipating a loss of 16 cents per share on revenue of $41.11 million, indicating competitive pressures in the market.
- CrowdStrike Growth Target: CrowdStrike Holdings, Inc. (NASDAQ:CRWD) will release its earnings after Tuesday's close, with investors keen to see if it can achieve at least 50% year-over-year growth in net new ARR, confirming its 20% growth trajectory and justifying its premium valuation.
- Broadcom Earnings Focus: Broadcom Inc. (NASDAQ:AVGO) is expected to report its Q1 results on Wednesday afternoon, with analysts forecasting EPS of $2.02 on revenue of $19.14 billion, while investors will be watching if AI semiconductor revenue doubles to $8.2 billion.
- JD.com Earnings Preview: JD.com, Inc. (NASDAQ:JD) is expected to release its results before Thursday's open, with Wall Street predicting a loss of 3 cents per share and revenue of $50.22 billion, reflecting the challenges and opportunities in the Chinese e-commerce market.
See More
Weekly Roundup: Cannabis and Psychedelic Sector Developments
- Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
- Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
- Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
- Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
See More
Organigram Secures CAD 65.2 Million Investment
- Investment Confirmation: Organigram Global Inc. confirmed a CAD 65.2 million private placement investment from a subsidiary of British American Tobacco, indicating strengthened financial health and increased market confidence.
- Financing Details: The financing includes the subscription of 14,027,074 shares at CAD 3.00 per share (totaling CAD 42.08 million) and the exercise of top-up rights for 9,897,356 shares at CAD 2.335854 per share (totaling CAD 23.12 million), culminating in gross proceeds of CAD 65.2 million.
- Market Reaction: Following the investment confirmation, Organigram's stock rose 8.70% in Thursday's premarket trading, reflecting investor optimism about the company's future, while the stock is currently trading 4.8% above its 20-day simple moving average.
- Earnings Outlook: Organigram is set to provide its next financial update on May 11, 2026, with EPS estimates dropping from 22 cents to a loss of 1 cent, while revenue estimates are expected to rise from CAD 45.70 million to CAD 54.67 million, indicating potential value opportunities.
See More
British American Tobacco Invests C$65.2M in Organigram Acquisition
- Investment Scale: British American Tobacco's C$65.2M private placement for Organigram's Sanity Group acquisition underscores its commitment to emerging markets, likely enhancing Organigram's competitive position.
- Share Subscription: Under the agreement, BAT will subscribe to approximately 14.02 million Organigram shares at C$3.00 each, generating about C$42.1M, which will further solidify its equity stake in Organigram.
- Use of Funds: The proceeds from this financing will be combined with existing cash and up to C$60M in credit facilities from ATB Financial to fund the cash portion of the Sanity acquisition and cover transaction costs, ensuring a smooth acquisition process.
- Market Reaction: Organigram's shares rose by 4.35% in premarket trading, reflecting positive market sentiment towards this investment and acquisition plan, which may enhance the company's long-term growth potential.
See More
Doseology Launches New Energy Pouches Targeting Market Opportunities
- Market Growth Potential: The global oral nicotine pouch market is projected to grow from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% CAGR, indicating strong consumer demand for smoke-free alternatives and driving investments and innovations from companies like Doseology.
- Product Innovation and Market Testing: Doseology's launch of Feed That Brain energy pouches in the U.S. marks its first direct-to-consumer initiative, aiming to provide sugar-free, smoke-free energy supplements, signifying the company's strategic positioning in the non-nicotine energy product sector, expected to attract health-conscious consumers.
- Strategic Leadership Change: The recent appointment of Larry Latowsky as Executive Chairman brings extensive industry experience from his tenure as President and CEO of Katz Group Canada, which is anticipated to drive sustainable growth in Doseology's oral stimulant platform and enhance market competitiveness.
- Equity Incentive Program: The company granted 140,000 restricted share units and 210,000 performance share units to a director, with the vesting schedule spread over 36 months, aimed at attracting and retaining executive talent to support the company's long-term strategic goals.
See More
Doseology Launches New Energy Pouches Targeting Market Opportunities
- Market Growth Potential: The global oral nicotine pouch market is projected to grow from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% CAGR, indicating strong consumer demand for smoke-free alternatives and creating market opportunities for companies like Doseology.
- Product Innovation Launch: Doseology has launched its 'Feed That Brain' energy pouches in the U.S., marking its first direct-to-consumer initiative aimed at providing sugar-free, smoke-free energy supplements that align with modern consumer preferences for health and convenience.
- Strategic Milestone: This U.S. pilot project represents a significant step for Doseology in validating oral pouch delivery as a scalable stimulant platform, with plans to evaluate consumer adoption and repeat purchase behavior, particularly targeting the demand for alternatives to traditional energy drinks.
- Leadership Change: Doseology recently appointed Larry Latowsky as Executive Chairman, whose experience from Katz Group Canada is expected to provide strategic guidance, enhance team confidence, and drive the release of long-term value.
See More
Major Retailers Continue Earnings Season This Week
- AST SpaceMobile Earnings Outlook: AST SpaceMobile, Inc. (NASDAQ:ASTS) is set to report its Q4 results after Monday's close, with Wall Street anticipating a loss of 16 cents per share on revenue of $41.11 million, indicating competitive pressures in the market.
- CrowdStrike Growth Target: CrowdStrike Holdings, Inc. (NASDAQ:CRWD) will release its earnings after Tuesday's close, with investors keen to see if it can achieve at least 50% year-over-year growth in net new ARR, confirming its 20% growth trajectory and justifying its premium valuation.
- Broadcom Earnings Focus: Broadcom Inc. (NASDAQ:AVGO) is expected to report its Q1 results on Wednesday afternoon, with analysts forecasting EPS of $2.02 on revenue of $19.14 billion, while investors will be watching if AI semiconductor revenue doubles to $8.2 billion.
- JD.com Earnings Preview: JD.com, Inc. (NASDAQ:JD) is expected to release its results before Thursday's open, with Wall Street predicting a loss of 3 cents per share and revenue of $50.22 billion, reflecting the challenges and opportunities in the Chinese e-commerce market.
See More
Weekly Roundup: Cannabis and Psychedelic Sector Developments
- Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
- Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
- Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
- Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
See More
Organigram Secures CAD 65.2 Million Investment
- Investment Confirmation: Organigram Global Inc. confirmed a CAD 65.2 million private placement investment from a subsidiary of British American Tobacco, indicating strengthened financial health and increased market confidence.
- Financing Details: The financing includes the subscription of 14,027,074 shares at CAD 3.00 per share (totaling CAD 42.08 million) and the exercise of top-up rights for 9,897,356 shares at CAD 2.335854 per share (totaling CAD 23.12 million), culminating in gross proceeds of CAD 65.2 million.
- Market Reaction: Following the investment confirmation, Organigram's stock rose 8.70% in Thursday's premarket trading, reflecting investor optimism about the company's future, while the stock is currently trading 4.8% above its 20-day simple moving average.
- Earnings Outlook: Organigram is set to provide its next financial update on May 11, 2026, with EPS estimates dropping from 22 cents to a loss of 1 cent, while revenue estimates are expected to rise from CAD 45.70 million to CAD 54.67 million, indicating potential value opportunities.
See More
British American Tobacco Invests C$65.2M in Organigram Acquisition
- Investment Scale: British American Tobacco's C$65.2M private placement for Organigram's Sanity Group acquisition underscores its commitment to emerging markets, likely enhancing Organigram's competitive position.
- Share Subscription: Under the agreement, BAT will subscribe to approximately 14.02 million Organigram shares at C$3.00 each, generating about C$42.1M, which will further solidify its equity stake in Organigram.
- Use of Funds: The proceeds from this financing will be combined with existing cash and up to C$60M in credit facilities from ATB Financial to fund the cash portion of the Sanity acquisition and cover transaction costs, ensuring a smooth acquisition process.
- Market Reaction: Organigram's shares rose by 4.35% in premarket trading, reflecting positive market sentiment towards this investment and acquisition plan, which may enhance the company's long-term growth potential.
See More
